Xolair

Rapt pays $35M for challenger to Novartis, Roche drug

Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a long-acting rival to Xolair.

Nick Paul Taylor Dec 23, 2024 8:10am

soccer kick off ball football field play game crowd boots cleats

Celldex laces up next to Big Pharmas with chronic hive drug

Nov 6, 2023 10:17am